Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phytopharm initiates safety and tolerability study of PYM-50028 in PD

April 21, 2009

Forest and Cypress launch Savella for fibromyalgia

April 21, 2009

Impax provides clinical update on IPX-066 and IPX-056

April 21, 2009

Cannabinoid CB2 modulators claimed by Kalypsys as analgesics

April 21, 2009

PAION initiates phase Ib study of CNS-7056 in volunteers undergoing colonoscopy

April 20, 2009

Dainippon discontinues development of AC-3933 for dementia

April 20, 2009

GSK reports novel glycine transporter inhibitors for schizophrenia treatment

April 20, 2009

Copaxone approved by Health Canada for isolated syndrome suggestive of MS

April 17, 2009

Accera forms wholly owned subsidiary, Neuera Pharmaceuticals

April 16, 2009

XenoPort exercises co-promotion option contained in agreement with GSK for Solzira

April 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...